文献速递银屑病与炎症性皮肤病

比美吉珠单抗治疗中重度斑块状银屑病两年中期结果

Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis: Two-year interim results from the open-label extension of the randomized BE RADIANT phase 3b trial.
PubMed 文献 · J Am Acad Dermatol · 2023-05-12

BE RADIANT 3b期随机对照试验开放标签延长期显示,第48周比美吉珠单抗组完全皮损清除(PASI 100)率高于司库奇尤单抗组(74.8% vs 52.8%)。持续比美吉珠单抗治疗者第96周PASI 100应答维持(70.8%),由司库奇尤单抗转换者第96周应答率升高至76.6%。安全性特征与已知一致。

要点

  • 第48周PASI 100:比美吉珠单抗组74.8%,司库奇尤单抗组52.8%。
  • 持续比美吉珠单抗治疗者第96周PASI 100应答率为70.8%。
  • 由司库奇尤单抗转换至比美吉珠单抗者第96周PASI 100应答率为76.6%。

核心结论

  • 比美吉珠单抗治疗48周获得的高PASI 100应答维持至第96周。
  • 由司库奇尤单抗转换至比美吉珠单抗的患者至第96周获得相似应答。

研究设计与样本

  • BE RADIANT 3b期随机对照试验,包括48周双盲期和开放标签延长期(OLE)。
  • 双盲期内患者接受比美吉珠单抗320 mg每4周或每8周,或司库奇尤单抗300 mg(第4周前每周,之后每4周)。
  • 自第48周起,所有患者在OLE中接受比美吉珠单抗治疗。

主要发现

  • 第48周达到完全皮损清除(PASI 100;改良无应答者填补)的患者比例:比美吉珠单抗组74.8% vs 司库奇尤单抗组52.8%。
  • 持续比美吉珠单抗治疗患者第96周PASI 100应答率为70.8%。
  • 由司库奇尤单抗转换至比美吉珠单抗的患者第96周PASI 100应答率升高至76.6%。
  • 最常见不良事件为鼻咽炎、口腔念珠菌病和尿路感染。
  • 安全性数据与比美吉珠单抗已知安全性特征一致。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 种族多样性有限。
  • 与COVID-19大流行重叠。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Bimekizumab is a monoclonal IgG1 antibody that inhibits interleukin-17A/F. Bimekizumab is more efficacious than secukinumab over 1 year in the treatment of psoriasis. OBJECTIVE: Evaluate the safety and efficacy of bimekizumab through 2 years in patients with moderate to severe plaque psoriasis. METHODS: The BE RADIANT phase 3b randomized controlled trial consisted of a 48-week double-blinded period, where patients received bimekizumab (320 mg every 4 or 8 weeks) or secukinumab (300 mg weekly to Week 4, then every 4 weeks), and an open-label extension (OLE). From Week 48, all patients received bimekizumab in the OLE. RESULTS: At Week 48, more patients achieved complete skin clearance (PASI 100; modified non-responder imputation) with bimekizumab than secukinumab (74.8% vs 52.8%). PASI 100 responses were maintained to Week 96 in continuous bimekizumab patients (70.8%); patients who switched from secukinumab to bimekizumab had increased rates at Week 96 (76.6%). The most common adverse events were: nasopharyngitis, oral candidiasis, and urinary tract infection. Safety data were consistent with the known safety profile of bimekizumab. LIMITATIONS: Limited racial diversity; overlap with the COVID-19 pandemic. CONCLUSIONS: High PASI 100 responses achieved with bimekizumab over 48 weeks were sustained through Week 96; secukinumab patients who switched to bimekizumab achieved similar responses by Week 96.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Strober B, Paul C, Blauvelt A, et al. Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis: Two-year interim results from the open-label extension of the randomized BE RADIANT phase 3b trial. J Am Acad Dermatol. 2023. PMID: 37182701. doi:10.1016/j.jaad.2023.04.063

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。